Bronchopulmonary dysplasia

Jornal de Pediatria

Volumn 81, Issue 2, 2005, Pages 99-110

  Velloso Monte, Luciana F ^a,d   Da Silva Filho, Luiz Vicente F ^a   Miyoshi, Milton Harumi ^b,c   Rozov, Tatiana ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital e Maternidade Santa Joana   (Brazil)

^d Hospital and Maternity Santa Joana ^*  (Brazil)

Author keywords

Bronchopulmonary dysplasia; Corticosteroid; Mechanical ventilation; Oxygen therapy; Prevention; Progression; Treatment

Indexed keywords

BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DEXAMETHASONE; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INFLUENZA VACCINE; NITRIC OXIDE; OXYGEN; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RETINOL; SPIRONOLACTONE; STREPTOCOCCUS VACCINE; SUPEROXIDE DISMUTASE; SURFACTANT;

ARTIFICIAL VENTILATION; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DIETARY INTAKE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HYPERCALCIURIA; INCIDENCE; KIDNEY CALCIFICATION; LUNG DEVELOPMENT; LUNG DYSPLASIA; LUNG FUNCTION; LUNG INJURY; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MORTALITY; OXYGEN THERAPY; PATHOGENESIS; PRENATAL CARE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VITAMIN SUPPLEMENTATION; INFANT; NEWBORN; PATHOPHYSIOLOGY; PROGNOSIS;

BRONCHOPULMONARY DYSPLASIA; HUMANS; INFANT; INFANT, NEWBORN; PROGNOSIS;

EID: 28244449341     PISSN: 00217557     EISSN: 00217557     Source Type: Journal    
DOI: 10.2223/1314     Document Type: Review

References (53)

1. Silva Filho LVF. Doença pulmonar crônica neonatal. J Pediatr (Rio J). 1998;74:265-74.
2. Barrington KJ, Finer NN. Treatment of bronchopulmonary dysplasia. A review. Clin Perinatol. 1998;25:177-202.
3. Hazinski TA. Bronchopulmonary dysplasia. In: Chernik, V, editor. Disorders of the respiratory tract in children. Philadelphia: WB Saunders; 1990. p. 300-20.
4. Northway Jr WH, Rosan RG, Porter DY. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357-68.
5. Pursey VA, Macpherson RI, Chernick V. Pulmonary fibroplasia following prolonged artificial ventilation of the newborn infant. Can Med Assoc J. 1969;100:451-7.
6. Bancalari E, Abdenour GE, Feller R, Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr. 1979;95:819-23.
7. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82:527-32.
8. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163:1723-9.
9. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, et al. Variations in practice and outcomes in the Canadian NICU network 1996-1997. Pediatrics. 2000;106:1070-9.
10. Nievas FF, Chernick V. Bronchopulmonary dysplasia: an update for the pediatrician. Clin Pediatr. 2002;41:77-85.
11. Rojas MA, Gonzales A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126:605-10.
12. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. Pediatrics. 1990;86:728-36.
13. Cunha GS, Mezzacappa FF, Ribeiro JD. Fatores maternos e neonatais na incidência de displasia broncopulmonar em recémnascidos de muito baixo peso. J Pediatr (Rio J). 2003;79:550-6.
14. Clark RH, Gerstmann DR, Jobe AH, Moffitt ST, Slutsky AS, Yoder BA. Lung injury in neonates: causes, strategies for prevention, and long-term consequences. J Pediatr. 2001;139:478-86.
15. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998;53:81-94.
16. van Waarde WM, Brus F, Okken A, Kimpen JL. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J. 1997;10:886-90.
17. Lyon A. Chronic lung disease of prematurity. The role of intrauterine infection. Eur J Pediatr. 2000;159:789-802.
18. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev. 2002;(4):CD000501.
19. Verma RP, McCulloch KM, Worrell L, Vidyasagar D. Vitamin A deficiency and severe bronchopulmonary dysplasia in very low birthweight infants. Am J Perinatol. 1996;13:389-93.
20. De Dooy JJ, Mahieu LM, van Bever HP. The role of inflammation in the development of chronic lung disease in neonates. Eur J Pediatr. 2001;160:457-63.
21. Papoff P. Infection, neutrophils, and hematopoietic growth factors in the pathogenesis of neonatal chronic lung disease. Clin Perinatol. 2000;27:717-31.
22. Eber E, Zach MS. Paediatric origins of adult lung disease. Thorax. 2001;56:317-23.
23. Greenough A. Measuring respiratory outcome. Semin Neonatol. 2000;5:119-26.
24. Primhak RA. Discharge and aftercare in chronic lung disease of the newborn. Semin Neonatol. 2003;8:117-25.
25. Truffert P, Empana JP, Breart G, Saugstad OD, Goelz R, Halliday HL, et al. Treatment strategies for bronchopulmonary dysplasia with postnatal corticosteroids in Europe: the EURAIL survey. Acta Paediatr. 2003;92:948-51.
26. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999;76(Suppl 1):S29-40.
27. Williams O, Greenough A. Post-natal corticosteroid use. Eur J Pediatr. 2003;162:613-15.
28. American Academy of Pediatrics - Committee on Fetus and Newborn - Canadian Paediatric Society - Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109:330-8.
29. Doyle L, Davis P. Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. J Paediatr Child Health. 2000;36:101-7.
30. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (< 96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146.
31. Grier DG, Halliday HL. Corticosteroids in the prevention and management of bronchopulmonary dysplasia. Semin Neonatol. 2003;8:83-91.
32. Cole CH. Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease. Expert Opin Investig Drugs. 2000;9:53-67.
33. Jobe AH. Postnatal corticosteroids for preterm infants-do what we say, not what we do. N Engl J Med. 2004;350:1349-51.
34. Cole CH, Colton T, Shah BL, Abbasi S, MacKinnon BL, Demissie S, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl 3 Med. 1999;340:1005-10.
35. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2000;(2):CD001969.
36. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2003;(2):CD002057.
37. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatrics. 2001;1:1-14.
38. Cole CH. Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: routes of administration compared. Semin Neonatol. 2001;6:343-50.
39. Cole CH. Inhaled glucocorticoid therapy in infants at risk for neonatal chronic lung disease. J Asthma. 2000;37:533-43.
40. Auten RL, Vozzelli M, Clark RH. Volutrauma. What is it, and how do we avoid it? Clin Perinatol. 2001;28:505-15.
41. Jobe AH, Ikegami M. Prevention of bronchopulmonary dysplasia. Curr Opin Pediatr. 2001;13:124-9.
42. Shah PS. Current perspectives on the prevention and management of chronic lung disease in preterm infants. Paediatr Drugs. 2003;5:463-80.
43. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev. 2001;(1): CD001968.
44. Ho LY. Bronchopulmonary dysplasia and chronic lung disease of infancy: strategies for prevention and management. Ann Acad Med Singapore. 2002;31:119-30.
45. Brion LP, Primhak RA. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2002;(1):CD001453.
46. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2000;(2):CD001694. Review.
47. Update in: Cochrane Database Syst Rev. 2001;(2):CD001694.
48. Ng GY, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001;(3):CD003214.
49. Atkinson SA. Special nutritional needs of infants for prevention and recovery from bronchopulmonary dysplasia. J Nutr. 2001;131:S942-6.
50. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics. 1998;102:1211-6.
51. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-6.
52. Kennedy JD. Lung function outcome in children of premature birth. J Paediatr Child Health. 1999;35:526-1.
53. Böhm B, Katz-Salamon M. Cognitive development at 5.5 years of children with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed. 2003;88:F101-5.